Obesity Featured Articles

31. When Clinical Trials Don't Stop For War 1/23/2026

    When war halted clinical trials in Ukraine, sites adapted instead of shutting down. Dr. Anna Titkova explains how patients, investigators, and sponsors kept research moving when conditions were anything but stable.

32. 3 Clinical Research Attorneys Talk 2026 Trends 1/23/2026

    Three life sciences legal experts share what they see happening in the year ahead — and what should remain firmly in the past. 

33. Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders 1/23/2026

    Digital protocols could reduce manual effort and enable rapid and more consistent downstream study execution, reporting, and submission processes. TransCelereate BioPharma's Rob DiCicco and Novartis' Bill Illis explain.

34. The Intelligent Teammate: Agentic AI As A Catalyst For Clinical Innovation 1/22/2026

    Agentic AI cuts variability, speeds clinical workflows, and strengthens compliance. It boosts efficiency and supports teams as research demands grow. Explore the full article for insights.

35. Early Phase Clinical Trial Enrollment: How To Avoid Delays From The Start 1/22/2026

    By operationalizing the early-phase strategies discussed in this article, trial teams can ensure that foundational safety and efficacy data are captured without the delays that derail studies.

36. Navigating Late-Phase Clinical Trial Enrollment: Strategies To Stay On Schedule 1/22/2026

    Late-phase trial delays cause massive revenue loss. This piece outlines AI pre-screening, direct-to-patient scaling, and retention tactics to hit study goals on time and ensure market readiness.

37. Integrating The Patient Pathway For Clinical Success 1/22/2026

    Explore how a unified workflow—integrating clinical fit validation with formal trial entry—minimizes friction and reduces the industry’s staggering 60–80% screen failure rates.

38. We Made Five Predictions For Clinical Research Last Year. Here's What Happened 1/22/2026

    Review 2025’s gap between AI discovery and trial execution, highlighting legislative and FDA shifts to help sponsors operationalize participant experience for 2026.

39. The "One-Trial" Trap: Why 2026's FDA Efficiency Push Actually Doubles Your Operational Risk 1/22/2026

    When it comes to the FDA's new "one-trial" shift, researcher Johnathon Anderson, Ph.D., warns: Do not confuse efficiency with leniency. Here, Anderson offers three factors to consider when adapting to new FDA trial expectations.

40. Common Issues And Trends In Clinical Research Vendor Qualification 1/21/2026

    Discover the biggest challenges in vendor qualification, including this one misalignment that affected more than half of surveyed respondents.